|
KMID : 1143820060020010017
|
|
Anxiety and Mood
2006 Volume.2 No. 1 p.17 ~ p.21
|
|
|
Efficacy and Safety of Venlafaxine Extended-release in Panic Disorder
|
|
Ryu Vin
Kim Chan-Hyung
|
|
|
Abstract
|
|
|
|
SSRIs have been considered as the first line of treatment for patients with panic disorder since 1990s along with cognitive behavioral treatments. High potency benzodiazepines (e.g. alprazolam, clonazepam) have had advantages in anti-panic effects. However, these drugs have limitations of treating panic disorder because of their dependency, tolerance and withdrawal. Serotonin and noradrenaline reuptake inhibitors (SNRIs) such as venlafaxine were introduced as antidepressants since 1990s. Recently, it is confirmed that SNRIs have the remarkable anti-panic effects although some concerns about its cost, tolerance, withdrawal, side effects such as dry mouth, constipation, and hypertension have emerged. In this regard, further study is required to confirm the efficacy of long term treatment of panic disorder. Despite these concerns, venla-faxine extended-release is an effective treatment in patients with panic disorder.
|
|
|
KEYWORD
|
|
|
Venlafaxine ER, Panic disorder, Serotonin noradrenaline reuptake inhibitor
|
|
|
FullTexts / Linksout information
|
|
|
|
|
|
Listed journal information
|
|
|
|